Clinical Trial

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 12, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a phase Ib/III, randomized, multicenter study evaluating the efficacy and safety of hepatic arterial infusion of paclitaxel cationic liposome in combination with systemic therapy (Oxaliplatin, Capecitabine, with or without Bevacizumab) as first-line treatment in colorectal liver metastases.
Trial Details
NCT Number NCT07117435
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Colorectal Liver Metastases, First-line Treatment
Enrollment 7 participants
Start Date 2025-05-13
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-12